Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone effect on Sugammadex reversal in pediatric surgery
NCT06623370Phase 4Completed
- Sponsor
- Konya City Hospital
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylprednisolone injection in postoperative pain and postoperative nausea and vomiting (PONV) (2 arms), sponsored by Konya City Hospital. Primary endpoint: Reversal Time of Rocuronium by Sugammadex at 2 hours. Started Oct 2024; status: completed.
02
Drugs
methylprednisolone injection
03
Conditions
postoperative painpostoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06623370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623370.